ArticleNeoplasia (New York, N.Y.)

Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.

Sophia Ran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.